|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13G
|
UNDER THE SECURITIES EXCHANGE ACT OF 1934
|
Aardvark Therapeutics, Inc. (Name of Issuer) |
Common Stock (Title of Class of Securities) |
002942100 (CUSIP Number) |
02/12/2025 (Date of Event Which Requires Filing of this Statement) |
| Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
 Rule 13d-1(b)
|
 Rule 13d-1(c)
|
| Rule 13d-1(d)
|
SCHEDULE 13G
|
| CUSIP No. | 002942100 |
| 1 | Names of Reporting Persons
Dr. Finian Tan | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
SINGAPORE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
1,828,258.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
8.69 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
IN |
SCHEDULE 13G
|
| CUSIP No. | 002942100 |
| 1 | Names of Reporting Persons
Christopher Michael Ho | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
UNITED STATES
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
1,694,894.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
7.92 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
IN |
SCHEDULE 13G
|
| CUSIP No. | 002942100 |
| 1 | Names of Reporting Persons
Vickers Venture Fund VI Pte. Ltd. | ||||||||
| 2 | Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
| ||||||||
| 3 | Sec Use Only | ||||||||
| 4 | Citizenship or Place of Organization
SINGAPORE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 9 | Aggregate Amount Beneficially Owned by Each Reporting Person
2,050,902.00 | ||||||||
| 10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
| ||||||||
| 11 | Percent of class represented by amount in row (9)
9.58 % | ||||||||
| 12 | Type of Reporting Person (See Instructions)
CO |
SCHEDULE 13G
|
| Item 1. | ||
| (a) | Name of issuer:
Aardvark Therapeutics, Inc. | |
| (b) | Address of issuer's principal executive offices:
4370 La Jolla Village Drive, Suite 1050, San Diego, California 92122 | |
| Item 2. | ||
| (a) | Name of person filing:
Dr. Finian Tan ("Dr. Tan")
Christopher Michael Ho ("Mr. Ho")
Vickers Venture Fund VI Pte. Ltd. ("Vickers Pte") | |
| (b) | Address or principal business office or, if none, residence:
The business address of each of the reporting persons is 1 Harbourfront Avenue, #16-06, Keppel Bay Tower, Singapore 098632 | |
| (c) | Citizenship:
Dr. Tan is a Singapore citizen. Mr. Ho is a United States citizen. Vickers Pte is a Singapore company. | |
| (d) | Title of class of securities:
Common Stock | |
| (e) | CUSIP No.:
002942100 | |
| Item 3. | If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: | |
| (a) | Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
| |
| (b) | Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
| |
| (c) | Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
| |
| (d) | Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
| |
| (e) | An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
| |
| (f) | An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
| |
| (g) | A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
| |
| (h) | A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
| |
| (i) | A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
| |
| (j) | A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution: | |
| (k) | Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
| |
| Item 4. | Ownership | |
| (a) | Amount beneficially owned:
Dr. Tan beneficially owns an aggregate of 1,861,258 shares of the Issuer's common stock representing (i) 20,000 shares held directly by Dr. Tan, (ii) 13,000 shares held by Dr. Tan's wife, (iii) 247,818 shares held by Vickers Venture Global Deep-tech Fund I L.P. ("Vickers DTF"), (iv) 225,354 shares held by Vickers Venture Fund VI (Plan) Pte. Ltd. ("Vickers Plan"), (iv) 1,221,722 shares held by Vickers Pte and (vi) 133,364 shares held by Vickers Venture Co-investment LLC ("Vickers Co-investment").
Mr. Ho beneficially owns an aggregate of 1,694,894 shares of the Issuer's common stock representing (i) 247,818 shares held by Vickers DTF, (ii) 225,354 shares held by Vickers Plan and (iii) 1,221,722 shares held by Vickers Pte.
Vickers Pte beneficially owns an aggregate of 2,050,902 shares of the Issuer's common stock held directly.
Vickers DTF is managed by its general partner Vickers Venture Partners V Ltd. which is in turn managed by its directors, Dr. Tan and Mr. Ho.
The sole shareholder of Vickers Plan is Vickers Venture Global Deep-tech Fund II (Plan) L.P. Vickers Venture Global Deep-tech Fund II (Plan) L.P. is managed by its general partner Vickers Venture Partners VI (CI) Ltd which is in turn managed by its directors, Dr. Tan and Mr. Ho.
Vickers Pte has two shareholders that each control the voting and disposition of an allocable portion of its securities, one of which is Vickers Venture Global Deep-tech Fund II (CI) L.P., which is managed by its general partner Vickers Venture Partners VI (CI) Ltd. which is in turn managed by its directors, being Dr. Tan and Mr. Ho.
Vickers Co-investment is managed by Vickers Venture Partners (S) Pte. Ltd. which is in turn managed by its two directors, one of which is Dr. Tan.
Each of Dr. Tan and Mr. Ho disclaims beneficial ownership of the securities held by such entities, except to the extent of his respective proportionate pecuniary interest therein. | |
| (b) | Percent of class:
Dr. Tan beneficially owns 8.69% of the Issuer's common stock. Mr. Ho beneficially owns 7.92% of the Issuer's common stock. Vickers Pte beneficially owns 9.58% of the Issuer's common stock. The percentage is based on an aggregate of 21,402,932 shares of the Issuer's common stock outstanding. | |
| (c) | Number of shares as to which the person has:
| |
| (i) Sole power to vote or to direct the vote:
Dr. Tan - 33,000
Mr. Ho - 0
Vickers Pte - 2,050,902 shares | ||
| (ii) Shared power to vote or to direct the vote:
Dr. Tan - 1,828,258 shares
Mr. Ho - 1,694,894 shares
Vickers Pte - 0 shares | ||
| (iii) Sole power to dispose or to direct the disposition of:
Dr. Tan - 33,000
Mr. Ho - 0
Vickers Pte - 2,050,902 shares | ||
| (iv) Shared power to dispose or to direct the disposition of:
Dr. Tan - 1,828,258 shares
Mr. Ho - 1,694,894 shares
Vickers Pte - 0 | ||
| Item 5. | Ownership of 5 Percent or Less of a Class. | |
| Item 6. | Ownership of more than 5 Percent on Behalf of Another Person. | |
Not Applicable
| ||
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. | |
Not Applicable
| ||
| Item 8. | Identification and Classification of Members of the Group. | |
Not Applicable
| ||
| Item 9. | Notice of Dissolution of Group. | |
Not Applicable
| ||
| Item 10. | Certifications: |
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. |
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
|
|
|
|